Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders (NRSily)

This study has been completed.
Information provided by (Responsible Party):
Peter Ferenci, Medical University of Vienna Identifier:
First received: May 19, 2008
Last updated: October 24, 2012
Last verified: October 2012
By chance the investigators found that iv. silibinin has a potent antiviral effect against the hepatitis C virus. Based on the results of the dose finding study (published) te optima dosing schedule is explored.This study will be evaluate whether the highest active dose given for the optimal time combined with standard of care will result in a sustained virologic response (=cure of hepatitis C).

Condition Intervention Phase
Hepatitis C
Drug: Silibinin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Study To Evaluate The Efficacy Of Silymarin In Addition To Combination-Therapy With Pegylated Interferon Alfa 2a (Peg-Ifn Alfa 2a) And Ribavirin In Patients With Chronic Hepatitis C

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • viral response at week 24 [ Time Frame: week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • sustained virologic response [ Time Frame: week 72 ] [ Designated as safety issue: No ]
  • Safety [ Designated as safety issue: Yes ]
    start to end of treatment

Estimated Enrollment: 100
Study Start Date: October 2007
Study Completion Date: June 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: on treatment nonresponders
naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
Drug: Silibinin
20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
Experimental: Nonresponders to previous antiviral combination therapy
Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy
Drug: Silibinin

comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days

sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion

Other Name: Silibinin infusions (20 mg/kg/d infused over 2 hours)given for 21 (either Monday -Friday or daily) or 28 days, continuation of antiviral combination therapy

Detailed Description:
Since the publication of the first data the optimal dosing schedule is investigated

Ages Eligible for Study:   19 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Nonresponders to full dose PEG-IFN/RBV therapy
  • Liver biopsy within the last 2 year

Exclusion Criteria:

  • Intolerance to one of the study drugs
  • Coinfection with HIV/HBV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00684268

Medical University of Vienna
Wien, Austria, A1090
Sponsors and Collaborators
Medical University of Vienna
  More Information

Responsible Party: Peter Ferenci, Prof. of Medicine, Medical University of Vienna Identifier: NCT00684268     History of Changes
Other Study ID Numbers: NRSili 
Study First Received: May 19, 2008
Last Updated: October 24, 2012
Health Authority: Austria: Federal Ministry for Health and Women

Keywords provided by Medical University of Vienna:
chronic hepatitis C
efficacy of iv. silibinin

Additional relevant MeSH terms:
Hepatitis C
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protective Agents processed this record on May 22, 2016